Saliva-based Screening Market

Saliva-based Screening Market Outlook (2024 to 2034)

The global saliva-based screening market is estimated to be worth US$ 374.9 million in 2024. The market is expected to register a CAGR of 8.0% from 2024 to 2034. The market is set to reach a projected value of US$ 810.9 million by 2034.

The demand for saliva-based screening is rising as it offers a promising alternative to blood-based diagnostics. It is a non-invasive and less intrusive method of collecting biological samples. It can be particularly useful in point-of-care settings and remote or underserved areas with limited access to healthcare facilities. Saliva collection is also more straightforward and less time-consuming than traditional blood draws, allowing for more frequent monitoring of health conditions and reducing the burden on healthcare systems.

Report Attributes	Details
Estimated Market Value (2024E)	US$ 374.9 million
Forecasted Market Value (2034F)	US$ 810.9 million
Global Market Growth Rate (2024 to 2034)	8.0% of CAGR
Diagnostics Segment Growth Rate (2024 to 2034)	8.4% of CAGR
North America Market Share (2024)	33.5%
East Asia Market Share (2024)	19.1%
Key Companies Profiled	Thermo Fisher Scientific, Inc. Neogen Corporation Abbott Sarstedt AG & Co.KG Autogen, Inc. Oasis Diagnostics Porex Salimetrics, LLC Takara Bio, Inc. Arcis Bio Orasure Technologies

What is Vitalizing the Demand for Saliva-based Screening Industry?

“The Non-invasive Nature of the Procedure and the Reduced Risk of Contamination is Vitalizing the Demand for Saliva-based Screening”

Non-invasive sampling has gained popularity recently due to its numerous advantages over traditional invasive methods. From a patient's perspective, saliva-based screening provides a more comfortable experience, eliminating the need for venipuncture or other invasive procedures. Saliva-based screening can be particularly beneficial for pediatric patients, elderly individuals, or those with needle phobias. The non-invasive nature of saliva collection may encourage more people to participate in screening programs, leading to higher compliance rates. It is crucial for public health initiatives and routine screenings where widespread participation is essential.

Saliva is rich in biomarkers that can provide valuable diagnostic information and insights into disease pathogenesis, making it an attractive source for researchers. The ease of sample collection and transport and the potential for rapid results make saliva-based testing an attractive option for developing point-of-care diagnostic devices. Additionally, the scalability of saliva-based screening makes it an ideal solution for mass screening programs, particularly during pandemics, where high-throughput testing is essential to control the spread of infectious diseases.

Manufacturers can also benefit from the scalability and user-friendliness of saliva-based screening, making it an appealing option for developing innovative diagnostic products. The ongoing research and technological advancements in saliva-based testing further underscore its potential as a versatile and patient-friendly diagnostic tool.

“Patient Convenience and its Applications in Infectious Disease Testing are other key Factors”

Ongoing advancements in technology and diagnostic methods have also improved the sensitivity and accuracy of saliva-based tests, boosting confidence in the reliability of results and making it a more viable option in healthcare. Public health initiatives, especially in response to pandemics or outbreaks, have further driven the adoption of saliva-based screening due to its efficiency, ease of use, and potential for large-scale testing.

Saliva-based screening has been widely explored for infectious disease testing, including detecting viruses such as SARS-CoV-2. The simplicity and less invasive nature of saliva testing can be crucial in managing and controlling the spread of infectious diseases. As the demand for saliva-based screening continues to evolve, new factors may emerge, but its potential to revolutionize healthcare screening and diagnostics must be addressed.

What are Some Lucrative Opportunities in the Saliva-based Screening Market?

“Ongoing Research expands Saliva-based Screening's Diagnostic potential from Personalized Medicine to Clinical Trials”

Ongoing research is identifying new biomarkers in saliva, which could expand the range of conditions diagnosed through saliva-based screening. With advancements in technology, saliva-based screening could contribute to the development of personalized medicine by allowing comprehensive biomarker profiling. Saliva-based screening could lead to treatments tailored to an individual's unique saliva profile, improving therapeutic outcomes. This is especially valuable in resource-limited settings or during public health emergencies, where quick and accurate diagnoses are essential.

Saliva-based screening can revolutionize how we diagnose and treat diseases, including autoimmune disorders, cardiovascular conditions, and neurodegenerative diseases. Integration of next-generation sequencing (NGS) and other high-throughput technologies could enhance the diagnostic accuracy and depth of information obtained from saliva samples. Saliva-based genomic analysis is another promising area of research. Integrating advanced genomic technologies, such as whole-genome sequencing, could uncover genetic information from saliva samples.

Application of mass spectrometry and other high-throughput proteomic techniques for in-depth profiling of saliva proteomes could enable a more comprehensive understanding of disease-related protein changes. Personalized medicine applications could be developed using saliva-based screening to predict individual medication responses and optimize drug therapies. Saliva-based assays could assess genetic variations influencing drug metabolism, efficacy, and potential adverse reactions, contributing to more effective and personalized treatment plans.

Saliva-based screening is gaining popularity in diagnostic laboratories for comprehensive disease profiling and population-scale screening, presenting an opportunity to enhance efficiency and reproducibility through the automation and standardization of saliva sample processing methodologies. For biopharmaceuticals and CROs, integrating saliva-based screening in clinical trials offers a non-invasive and patient-friendly approach to assess treatment responses and safety, making it a potential game-changer in patient monitoring, biomarker discovery, and pharmacogenomic studies.

Which are Some Threats Hindering the Saliva-based Screening Industry?

“Limited Biomarker Availability and Variability in Saliva Composition require ongoing efforts to ensure Reliable Results”

While saliva-based screening has shown promise in various areas, some critics argue that it may not be as sensitive or specific as traditional methods, especially for certain conditions. One of the key challenges in developing saliva-based tests is the limited availability of biomarkers. Not all biomarkers in blood or other bodily fluids are readily detectable in saliva, which may restrict the range of conditions that can be effectively screened using this approach.

Another challenge is ensuring the reliability of results. Saliva composition can vary between individuals and even within the same individual at different times, impacting test results' consistency and accuracy. Despite this challenge, significant progress has been made in establishing standardized protocols and validating the diagnostic accuracy of saliva-based tests. Regulatory bodies may require rigorous validation before approving these tests for widespread use.

“Need for increased Awareness, Regulatory Approval challenges, and Considerations regarding Cost-effectiveness compared to Traditional methods.”

There are many advantages, but there still needs to be more awareness and acceptance among the general population and healthcare professionals about the effectiveness of saliva-based screening. Educating healthcare providers and the public about the benefits of this method is critical for its widespread acceptance and adoption. Regulatory approval is one of the significant hurdles to integrating saliva-based tests into mainstream healthcare practices. Achieving regulatory approval for these tests can be lengthy, as stringent regulatory requirements may pose a challenge. The regulatory bodies must ensure these tests meet the necessary safety and efficacy standards before approval.

Another important consideration is the cost-effectiveness of saliva-based tests compared to traditional methods. The development, production, and implementation of these tests need significant investment, and if the costs associated with them are high, it may impact their affordability and accessibility.

“Ensuring Diagnostic Accuracy and Regulatory Challenges to Hinder the Market Growth”

Manufacturers need to address the issue of diagnostic accuracy and ensure the reliability of these tests compared to traditional methods. False positives or negatives could lead to scepticism among healthcare professionals, regulatory bodies, and the general public. Producers must focus on sensitivity and specificity to build trust in saliva-based screening. Moreover, regulatory challenges and approval processes can cause significant delays in introducing saliva-based tests into clinical practice.

Stricter regulatory requirements may limit the market's growth potential, impacting the ability of manufacturers to bring innovative saliva-based screening products to market. Key players must navigate these regulatory landscapes effectively to ensure the timely and widespread adoption of saliva-based screening. Staying competitive and improving the performance and cost-effectiveness of saliva-based screening will be crucial to overcoming market threats and maintaining a strong position in the healthcare industry.

Country-wise Insights

The saliva-based screening industry finds a considerable portion of its user base in North America and East Asia. North America is predicted to hold 33.5% of the worldwide market share in 2024. The market is expected to progress at a CAGR of 7.6% for the forecast period.

East Asia is the other region with a considerable share of the market. In 2024, the share for East Asia is tipped to be 19.1%. The market is expected to register a promising CAGR of 9.3% in East Asia over the forecast period.

What is Augmenting the Saliva-based Screening Industry in the United States?

“The COVID-19 Pandemic, Public Health Initiatives, and Patient preferences for Comfort propel the United States.”

Attributes	Details
Market Value (2024E)	US$ 108 million
CAGR (2024 to 2034)	7.5%
Projected Value (2034F)	US$ 224 million

The value of the United States' saliva-based screening industry is estimated to be US$ 108 million in 2024. The market is expected to register a CAGR of 7.5% over the forecast period, reaching US$ 224 million by 2034.

Saliva-based screening in the United States has experienced significant growth and adoption in recent years, with several factors contributing to this trend. One of the primary drivers of this growth is the COVID-19 pandemic, which has accelerated the demand for non-invasive and comfortable testing alternatives. Public health agencies and initiatives in the United States have played a crucial role in promoting saliva-based testing for infectious and non-infectious diseases. Patient preferences for non-invasive testing methods have also fueled the demand for saliva-based screening, with patients increasingly opting for tests that offer a more comfortable and less intrusive experience.

Continuous advancements in technology, including molecular diagnostics and high-throughput screening techniques, have enhanced the sensitivity and specificity of saliva-based screening, boosting the confidence of healthcare professionals and researchers in the reliability of results. The integration of saliva-based screening with telehealth services has facilitated remote diagnostics and monitoring, becoming particularly relevant with the increased adoption of telehealth platforms in the United States. This has provided patients with convenient options for testing and consultation.

Why is the Demand for Saliva-based Screening Increasing steadily in the Chinese Market?

“Investments in Diagnostic Technology and Regulatory Facilitation Contributes to the Integration into the Healthcare System”

Attributes	Details
Market Value (2024E)	US$ 36 million
CAGR (2024 to 2034)	9.4%
Projected Value (2034F)	US$ 87 million

The value of the Chinese market for saliva-based screening is estimated to be US$ 36 million in 2024. The market is expected to register a CAGR of 9.4% over the forecast period, reaching US$ 87 million by 2034.

Saliva tests for SARS-CoV-2 have gained popularity due to their non-invasive nature, ease of collection, and reduced requirement for skilled healthcare personnel. This has allowed for mass testing initiatives, especially in densely populated areas.

China's investments in research and development, advances in diagnostic technologies, and regulatory support have facilitated the integration of these screenings into the healthcare system. Integrating saliva-based screening with telemedicine and digital health platforms enables remote testing and consultations, addressing healthcare needs in urban and rural areas. China's supportive government policies, regulations, and approvals for saliva-based screening have encouraged their development and commercialization, enhancing the accuracy and efficiency of screening.

Category-wise Insights

Why is the Diagnostics Segment Dominating the Saliva-based Screening Market?

Attributes	Details
Segment Value (2024E)	US$ 292.1 million
CAGR (2024 to 2034)	8.4%
Projected Value (2034F)	US$ 654.6 million

Saliva-based screening is gaining popularity among patients, manufacturers, and producers who recognize the benefits of this non-invasive diagnostic method. The ease of sample collection and the versatility of saliva-based screening in diagnosing various health conditions have made it a preferred choice for manufacturers and producers looking for a reliable and accurate diagnostic tool.

Manufacturers and producers can now develop and produce these tests on a larger scale, making them more accessible and affordable for patients. This leads to a significant increase in demand for these tests. As more healthcare professionals, patients, and manufacturers recognize the benefits of saliva-based diagnostics, the demand for these tests will continue to grow.

Competitive Landscape

Key players in the saliva-based screening market include Thermo Fisher Scientific, Inc., Neogen Corporation, Abbott, Sarstedt AG & Co.KG, Autogen, Inc., Oasis Diagnostics, Porex, Salimetrics, LLC, Takara Bio, Inc., Arcis Bio, and Orasure Technologies.

Leading companies such as Molbio Diagnostics and Testi Technologies and innovative players like Salilistic have critical roles in introducing groundbreaking technologies. These advancements include the development of rapid point-of-care saliva testing devices, expanding diagnostic applications beyond infectious diseases, and integrating cutting-edge genomic and proteomic analyses. Key players continue to invest in research and development, focusing on refining diagnostic accuracy, exploring novel biomarkers, and expanding the applications of saliva-based screening.

Recent Advancements :

• On December 15, 2023, Goa-based Molbio Diagnostics partnered with Finland's Testi Technologies to commercialize PROMILLESS, a saliva-based self-test kit for measuring body alcohol content. The collaboration aimed to enhance accessibility and advance diagnostics.
• On August 28, 2023, researchers explored the potential of automated, saliva-based PCR testing for COVID-19 surveillance. A study on the medRxiv preprint server detailed implementing a PCR testing program in an educational institution.
• Launched on June 21, 2023, the world's first saliva-based pregnancy test, Salilistic, revolutionized pregnancy detection in the UK. Eliminating the need for urine marked a significant advancement in home pregnancy testing.

Segmentation of the Saliva-based Screening Market

• By Product Type :

  • Saliva Collection Kits
  • Saliva Nucleic Acid Purification Kits,
  • Saliva Based Detection Kits

• By Purpose :

  • Research Use Only
  • Diagnostics

• By Application :

  • Infection Analysis/Detection (Non- COVID)
  • Genomic Analysis
  • Proteomics
  • Pharmacogenomics
  • Liquid biopsy

• By End User :

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Academic and Research Institutes
  • Biopharmaceuticals and CROs

• By Region :

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia & Oceania
  • Middle East & Africa